Ovarian cancer vaccine (Northwest Biotherapeutics)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOvarian cancer vaccine (Northwest Biotherapeutics)
Drug Alias NameAutologous dendritic cell vaccine (DCVax-L) for recurrent ovarian or primary peritoneal cancer - Northwest BiotherapeuticsAutologous dendritic cell vaccine leaded with autologous tumour cell lysate (DCVax-L) - Northwest Biotherapeuticsdendritic cell-based immunotherapy (ovarian cancer)DCVac-L - Northwest BiotherapeuticsDCVax-L (Ovarian) +[7] 
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsOvarian NeoplasmsPeritoneal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNorthwest Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNorthwest Biotherapeutics IncUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A